A Study for Treatment of Partial Seizures in Children
This study has been completed.
Sponsor:
Abbott
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00102713
First received: February 1, 2005
Last updated: May 17, 2007
Last verified: May 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to assess the safety profile of the investigational medication, Depakote Sprinkle Capsules, in the treatment of partial seizures in children ages 3-10.
| Condition | Intervention | Phase |
|---|---|---|
|
Partial Seizures |
Drug: Divalproex Sodium (Depakote Sprinkle Capsules) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open Label Study for Treatment of Partial Seizures in Children |
Resource links provided by NLM:
Genetics Home Reference related topics:
pyridoxal 5'-phosphate-dependent epilepsy
MedlinePlus related topics:
Seizures
U.S. FDA Resources
Further study details as provided by Abbott:
Eligibility| Ages Eligible for Study: | 3 Years to 10 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Subject has diagnosis of partial seizures with/without secondary generalization, supported by:
- Observed ictal events consistent with partial seizures with/without secondary generalization; Documented by reliable observers
1 of following 3:
- EEG at some time in past demonstrating focal abnormalities consistent with partial seizures
- If the EEG is inconclusive or does not support partial seizures, then an MRI/CT will be done
- If the MRI/CT fails to support a diagnosis of partial seizures, the subject may still qualify based on the principal Investigator's clinical diagnosis
- Subject weighs at least 15 kg (33 lbs).
- Parent/caregiver is able to keep an accurate seizure diary.
Exclusion Criteria:
- Has had status epilepticus in the past 3 months prior to Screening
- Has a history of any of: Cardiac (including clinically important abnormality on ECG); Renal; Psychiatric (including psychosurgery); Oncologic; Endocrine; Metabolic; Pancreatic; Hepatic disease (including clinical/serological history of hepatitis); Urea cycle disorder
- Has: Expanding CNS neoplasm; Active CNS infection; Demyelinating disease; Degenerative neurological disease; Progressive encephalopathy; or any Progressive CNS disease
- Has platelet count less than or equal to 100,000/mcL
- Has blood chemistry ALT/AST value(s) greater than or equal to 2 times upper limit of normal at screening
- Requires anticoagulant drug therapy
- Receiving systemic chemotherapy
- Requires treatment with aspirin
- Subject is pregnant
- Has been on ketogenic diet within 30 days prior to screening
- Considered by investigator to be non-responder to valproate for treatment of epilepsy (e.g., Despite adequate trial with serum concentrations of 60 mcg/mL or greater, subject continues to have inadequate seizure control)
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00102713
Locations
| United States, Alabama | |
| Neurology Clinic, P.C. | |
| Northport, Alabama, United States | |
| United States, Arizona | |
| St. Joseph's Hospital and Medical Center | |
| Phoenix, Arizona, United States, 85013 | |
| United States, Florida | |
| Pediatric Epilepsy and Neurology Specialists | |
| Tampa, Florida, United States | |
| United States, Georgia | |
| Child Neurology Associates, P.C. | |
| Atlanta, Georgia, United States | |
| United States, Ohio | |
| Akron Children’s Hospital | |
| Akron, Ohio, United States, 44308 1062 | |
| University Hospitals of Cleveland | |
| Cleveland, Ohio, United States, 44106 | |
| United States, Texas | |
| Texas Association of Pediatric Neurology, P.A. | |
| San Antonio, Texas, United States | |
| United States, Virginia | |
| Monarch Medical Research | |
| Norfolk, Virginia, United States, 23510 | |
| Virginia Commonwealth University Medical Center | |
| Richmond, Virginia, United States, 23298-0211 | |
| United States, Wisconsin | |
| Richard V. Colan, M.D., S.C. | |
| Milwaukee, Wisconsin, United States, 53226 | |
Sponsors and Collaborators
Abbott
Investigators
| Study Director: | Global Medical Information 800-633-9110 | Abbott |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00102713 History of Changes |
| Other Study ID Numbers: | M04-714 |
| Study First Received: | February 1, 2005 |
| Last Updated: | May 17, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Abbott:
|
Partial Seizures |
Additional relevant MeSH terms:
|
Seizures Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms Valproic Acid Anticonvulsants Central Nervous System Agents Therapeutic Uses |
Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action GABA Agents Neurotransmitter Agents Physiological Effects of Drugs Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs |
ClinicalTrials.gov processed this record on May 21, 2013